Tunable cytotoxic aptamer–drug conjugates for the treatment of prostate cancer

Aptamer-Drug Conjugates of Active Metabolites of Nucleoside Analogs and Cytotoxic Agents Inhibit Pancreatic Tumor Cell Growth

(2017) Sorah Yoon et al.   Molecular Therapy-Nucleic Acids

A phase 1 clinical trial of ASG-5ME, a novel drug-antibody conjugate targeting SLC44A4, in patients with advanced pancreatic and gastric cancers

(2016) Andrew L. Coveler et al.   INVESTIGATIONAL NEW DRUGS

Pre-existing anti–polyethylene glycol antibody linked to first-exposure allergic reactions to pegnivacogin, a PEGylated RNA aptamer

(2016) Nancy J. Ganson et al.   JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY

The Discovery and Preclinical Development of ASG-5ME, an Antibody-Drug Conjugate Targeting SLC44A4-Positive Epithelial Tumors Including Pancreatic and Prostate Cancer

(2016) M. Mattie et al.   MOLECULAR CANCER THERAPEUTICS

From the RNA world to the clinic

(2016) B. A. Sullenger et al.   SCIENCE

Advances in the development of aptamer drug conjugates for targeted drug delivery

(2016) Ke Chen et al.   Wiley Interdisciplinary Reviews-Nanomedicine and Nanobiotechnology

Improved Synthesis andIn VitroEvaluation of an Aptamer Ribosomal Toxin Conjugate

(2016) Linsley Kelly et al.   Nucleic Acid Therapeutics

From selection hits to clinical leads: progress in aptamer discovery

(2016) Keith E Maier et al.   Molecular Therapy-Methods & Clinical Development

Cutaneous adverse effects of targeted therapies

(2015) James B. Macdonald et al.   JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY

Toxicity of targeted therapy: Implications for response and impact of genetic polymorphisms

(2014) Sariah Liu et al.   CANCER TREATMENT REVIEWS

A General RNA Motif for Cellular Transfection

(2012) Maria LB Magalhães et al.   MOLECULAR THERAPY

An RNA Alternative to Human Transferrin: A New Tool for Targeting Human Cells

(2012) Samantha E Wilner et al.   Molecular Therapy-Nucleic Acids

In Vitro and In Vivo Responses of Advanced Prostate Tumors to PSMA ADC, an Auristatin-Conjugated Antibody to Prostate-Specific Membrane Antigen

(2011) X. Wang et al.   MOLECULAR CANCER THERAPEUTICS

PC3 is a cell line characteristic of prostatic small cell carcinoma

(2011) Sheng Tai et al.   PROSTATE

Phase 1b Randomized Study of Antidote-Controlled Modulation of Factor IXa Activity in Patients With Stable Coronary Artery Disease

(2008) Mark Y. Chan et al.   CIRCULATION

A randomized, repeat-dose, pharmacodynamic and safety study of an antidote-controlled factor IXa inhibitor

(2008) M. Y. CHAN et al.   JOURNAL OF THROMBOSIS AND HAEMOSTASIS